Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk gains approval in China for blockbuster drug Wegovy. More than 11% of all adults in China live with diabetes - more than any other country in the world. Both Eli Lilly and Novo Nordisk are disrupting the diet industry with their GLP-1 drugs, offering the potential for significant growth in the future.

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.

Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion

American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) rose Tuesday on the New York Stock Exchange (NYSE) after the company announced that its popular weight-loss drug Wegovy has been approved to start being sold in China.

Novo Nordisk Rises as Wegovy Is Approved in China

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Why Novo Nordisk (NVO) is a Top Stock for the Long-Term

Pfizer

Novo Nordisk is raking in billions from Ozempic and Wegovy. Pfizer wants in on the action, so it's teaming up with a biotech.

Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?

Novo Nordisk has gained approval to start marketing its blockbuster weight-loss drug Wegovy in China, opening the door for the Danish pharmaceutical giant to further boost sales of the medicine that has transformed it into Europe's most valuable company.

Novo Nordisk gains approval to sell weight-loss drug Wegovy in China

Novo Nordisk (NYSE: NVO ) stock rose on news that China has approved its weight loss drug Wegovy and that the drugmaker will invest $4.1 billion into expanding its U.S. production capacity. The expansion will be built in North Carolina and is part of a $11 billion global production push.

NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug

Novo Nordisk A/S (CPH: NOVO-B) climbed 3.0% to an all-time high on Tuesday after China approved the sale of its weight-loss treatment Wegovy.  Year-to-date, shares of the pharmaceutical giant are now up a whopping 45%.

Novo Nordisk wins approval for its weight-loss drug from China

Ozempic maker Novo Nordisk confirmed Tuesday its popular weight loss drug Wegovy had been approved for sale in China, a key victory for the Danish firm that opens the door to an enormous market, but the company told Forbes it will only launch there once it could guarantee supplies for those already taking it as shortages plague the U.S. market and elsewhere.

Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid Shortages

Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management. The approval opens up the blockbuster drug for sale for those with obesity and at least one weight-related comorbidity.

Novo Nordisk's Wegovy weight loss drug approved in China

Novo Nordisk (NYSE:NVO) is investing $4.1 billion to expand its US manufacturing, focusing on its high-demand weight-loss drugs, Ozempic and Wygovy. The investment will fund a new 1.4 million square foot plant near Raleigh, North Carolina, doubling the site's size.

Ozempic maker Novo Nordisk to spend $4.1bn on North Carolina facility

Novo Nordisk's drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday.

Novo Nordisk says Semaglutide approved for long-term weight management in China

Novo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company's weight loss and diabetes drugs Wegovy and Ozempic, the Danish firm said Monday.

Novo Nordisk Invests $4.1 Billion For New US Facility—Boosting Ozempic Production

Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on Monday.

Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing

In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*.

Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline

Novo Nordisk said it will spend $4.1 billion to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies.  The investment will fund a new manufacturing plant in Clayton, North Carolina, responsible for filling and packaging syringes and injection pens for the drugs.

Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic

Teva Pharmaceutical

Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

China's National Medical Products Administration has granted green lights for Novo Nordisk's insulin icodec injection used for the treatment of Type-2 diabetes among adults to enter the Chinese market, it said on Monday.

China OKs Novo Nordisk's Type-2 diabetes treatment to enter its market

Amazon

Chipotle

Microsoft

Netflix

NVIDIA

Walmart

If you are tired of waiting for a rate cut, for the economy to improve and for consumer sentiment to soar so your portfolio turns green, it is best to consider rebalancing it. Several blue-chip stocks in the industry are unaffected by the market's ups and downs and have a steady history of outperforming the market.

7 Strong Buy Blue-Chip Stocks to Keep You in the Green

Novo Nordisk's popular obesity drug Wegovy helped women with a common heart disease lose more weight than men who had the same condition, an analysis of study data published in a medical journal has shown.

Novo's Wegovy induces higher weight loss in women than men with same heart condition, study shows

FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8

Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A

AbbVie

Eli Lilly

Recently, the biotech industry has taken a bit of a slower stance toward growth. With the Covid-19 pandemic in the rearview mirror, the focus of major pharmaceutical developers and biotech companies shifted back toward chronic diseases like diabetes, cancer, and heart disease.

3 Biotech Stocks to Buy Now: June 2024

Catalent

Sarepta Therapeutics

Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.

Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty

Novo Nordisk's top-two blockbuster drugs include the same active ingredient -- semaglutide. The company is testing an even higher-dose version of semaglutide, which may yield even better results.

The Best Could Be Yet to Come for Novo Nordisk and Ozempic

Advanced Micro Devices

Intuitive Surgical

New Linde PLC

MercadoLibre

Southern Company

Toyota Motor

Earnings are exactly what they sound like. They're everything that's left over after everything else has been paid.

News for Novo Nordisk Stock (NVO)